Evidence map›Paper›PMID 34445359›Full record

ReviewInternational journal of molecular sciences2021

From Menopause to Neurodegeneration-Molecular Basis and Potential Therapy.

Yu-Jung Cheng, Chieh-Hsin Lin, Hsien-Yuan Lane

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yu-Jung ChengDepartment of Physical Therapy and Graduate Institute of Rehabilitation Science, China Medical University, Taichung 40402, Taiwan.
Chieh-Hsin LinInstitute of Clinical Medical Science, China Medical University, Taichung 40402, Taiwan.
Hsien-Yuan LaneInstitute of Clinical Medical Science, China Medical University, Taichung 40402, Taiwan.ORCID 0000-0003-2162-8174

Funding

Chang Gung Memorial Hospital CMRPG8G1391Chang Gung Memorial Hospital CMRPG8K1161Chang Gung Memorial Hospital CMRPG8K1461China Medical University, Taiwan CMU104-S-14-04Ministry of Science and Technology, Taiwan 108-2410-H-039-009-MY2Ministry of Science and Technology, Taiwan 110-2314-B-182A-048 -Ministry of Science and Technology, Taiwan MOST 109-2628-B-182A-002National Health Research Institutes NHRI-EX110- 10816NC
6 · The paper itself

Abstract

The impacts of menopause on neurodegenerative diseases, especially the changes in steroid hormones, have been well described in cell models, animal models, and humans. However, the therapeutic effects of hormone replacement therapy on postmenopausal women with neurodegenerative diseases remain controversial. The steroid hormones, steroid hormone receptors, and downstream signal pathways in the brain change with aging and contribute to disease progression. Estrogen and progesterone are two steroid hormones which decline in circulation and the brain during menopause. Insulin-like growth factor 1 (IGF-1), which plays an import role in neuroprotection, is rapidly decreased in serum after menopause. Here, we summarize the actions of estrogen, progesterone, and IGF-1 and their signaling pathways in the brain. Since the incidence of Alzheimer's disease (AD) is higher in women than in men, the associations of steroid hormone changes and AD are emphasized. The signaling pathways and cellular mechanisms for how steroid hormones and IGF-1 provide neuroprotection are also addressed. Finally, the molecular mechanisms of potential estrogen modulation on N-methyl-d-aspartic acid receptors (NMDARs) are also addressed. We provide the viewpoint of why hormone therapy has inconclusive results based on signaling pathways considering their complex response to aging and hormone treatments. Nonetheless, while diagnosable AD may not be treatable by hormone therapy, its preceding stage of mild cognitive impairment may very well be treatable by hormone therapy.

Indexed as

Nerve DegenerationAgingAlzheimer DiseaseAnimalsBrainEstrogen Replacement TherapyFemaleHumansMenopausePostmenopauseRisk FactorsAlzheimer’s diseaseestrogenIGF-1menopauseneurodegenerative diseaseNMDAR

Identifiers

PMID34445359
PMCPMC8395405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.